MFF-Derived Peptides Targeting VDAC1 for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer lack effective targeting of mitochondrial cell death mechanisms, particularly in non-small cell lung cancer and other drug-resistant tumor types, due to the elusive nature of regulators of mitochondrial dynamics.
Innovation Solution
Development of Mitochondrial Fission Factor (MFF)-derived peptides and peptide mimetics that target the voltage-dependent anion channel-1 (VDAC1), disrupting the MFF-VDAC1 complex to induce mitochondrial depolarization and trigger cell death in cancer cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current cancer therapies are used, then general treatment is provided, but effective targeting of mitochondrial cell death mechanisms is lacking
Solution Approach 1:
The invention segments the MFF protein into a specific peptide sequence (amino acids 223-243) that can be delivered independently to target VDAC1. This segmentation allows the therapeutic agent to specifically target mitochondrial cell death mechanisms without requiring delivery of the entire MFF protein, thereby improving targeting capability while maintaining therapeutic effectiveness.
Solution Approach 2:
The MFF-derived peptide acts as an intermediary that bridges the therapeutic goal (inducing mitochondrial cell death) and the target (VDAC1). The peptide mimics the natural MFF-VDAC1 interaction, serving as a mediator that can be delivered systemically while achieving specific intracellular targeting of the mitochondrial voltage-dependent anion channel.
2Adaptability or versatility
If MFF-derived peptides are developed to target VDAC1, then specific mitochondrial targeting is achieved, but the complexity of peptide design and optimization increases
Solution Approach 1:
The invention extracts the critical functional domain from the full MFF protein, isolating amino acids 223-243 as the minimal sequence required for VDAC1 binding and mitochondrial targeting. This extraction simplifies the therapeutic agent from a large protein to a small peptide, reducing design and delivery complexity while maintaining specific mitochondrial targeting capability.
Solution Approach 2:
The invention optimizes specific parameters of the peptide sequence, including the critical arginine residues (Arg225, Arg236) and glutamine (Gln241) that mediate VDAC1 binding. By focusing optimization on these key parameters rather than the entire protein sequence, the design process becomes more tractable while achieving high targeting specificity.
3Reliability
If peptidomimetics are used to disrupt MFF-VDAC1 complex, then cell death is triggered in cancer cells, but selective toxicity against normal cells must be ensured
Solution Approach 1:
The invention exploits local quality differences in MFF expression between cancer and normal cells. Since MFF is overexpressed in cancer cells relative to normal cells, the MFF-derived peptide selectively disrupts MFF-VDAC1 complexes in cancer cells where the target is abundant, while having minimal effect on normal cells with lower MFF levels, thereby achieving selective anticancer activity with reduced toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MFF-derived peptides effectively inhibit tumor cell growth and induce cell death in various cancer types, including drug-resistant melanoma, with preclinical models showing well-tolerated treatment and anticancer activity in patient-derived xenografts and organoids, highlighting the MFF-VDAC1 complex as a novel therapeutic target.
Implementation Method 1
MFF was observed to insert into the interior hole of the VDAC1 ring using Arg225, Arg236 and Gln241 as key contact sites
Data Source
AI summary
The present invention relates to Mitochondrial Fission Factor (MFF)-derived peptides or peptide mimetics and to methods of making MFF-derived peptides or peptide mimetics. Also provided are methods of treating a disease in a subject in need thereof, comprising administering to the subject an effective amount of a MFF-derived peptide or peptide mimetic.